Recursion Pharmaceuticals, Inc. (RXRX)Healthcare | Biotechnology | Salt Lake City, United States | NasdaqGS
3.61 USD
-0.55
(-13.341%) ⇩
(Oct. 16, 2026, 12:38 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 8:23 a.m. EDT
The long-term outlook is severely compromised by a four-year streak of negative annual returns, with the stock down over 70% from its peak. This persistent structural decline, combined with deteriorating fundamentals like negative revenue growth and significant cash burn, indicates a business struggling to find traction. While the short-term chart shows some recent recovery and the stock trades at a discount to its book value, the lack of earnings power and the heavy defensive positioning in the options market suggest this is a speculative trap rather than a turnaround candidate. Investors should avoid this security until there is clear evidence of sustained operational improvement. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.111559 |
| AutoETS | 0.112227 |
| AutoTheta | 0.129865 |
| AutoARIMA | 0.158768 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 33% |
| H-stat | 22.53 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.387 |
| Excess Kurtosis | -0.40 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 7.283 |
| Revenue per Share | 0.108 |
| Market Cap | 1,933,257,216 |
| Forward P/E | -4.00 |
| Beta | 1.03 |
| Website | https://www.recursion.com |
As of Oct. 10, 2026, 8:23 a.m. EDT: Speculators are positioning defensively with heavy put volume and open interest concentrated at strikes below the current price (3.0 and 4.0), while call activity remains thin and focused near-the-money. The dominance of downside protection suggests a consensus expectation of continued volatility and potential further declines rather than a breakout.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.29010236 |
| Address1 | 41 South Rio Grande Street |
| All Time High | 42.81 |
| All Time Low | 2.77 |
| Ask | 3.61 |
| Ask Size | 2 |
| Audit Risk | 10 |
| Average Analyst Rating | 2.4 - Buy |
| Average Daily Volume10 Day | 38,946,600 |
| Average Daily Volume3 Month | 21,168,662 |
| Average Volume | 21,168,662 |
| Average Volume10Days | 38,946,600 |
| Beta | 1.032 |
| Bid | 2.96 |
| Bid Size | 2 |
| Board Risk | 9 |
| Book Value | 1.71 |
| City | Salt Lake City |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.605 |
| Current Ratio | 5.034 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 4.185 |
| Day Low | 3.605 |
| Debt To Equity | 7.283 |
| Display Name | Recursion Pharmaceuticals |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,785,931,200 |
| Earnings Call Timestamp Start | 1,785,931,200 |
| Earnings Timestamp | 1,785,933,000 |
| Earnings Timestamp End | 1,793,795,400 |
| Earnings Timestamp Start | 1,793,795,400 |
| Ebitda | -471,604,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -3.706 |
| Enterprise To Revenue | 31.865 |
| Enterprise Value | 1,747,978,368 |
| Eps Current Year | -0.92558 |
| Eps Forward | -0.90189 |
| Eps Trailing Twelve Months | -1.09 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.6192 |
| Fifty Day Average Change | -0.014199972 |
| Fifty Day Average Change Percent | -0.003923511 |
| Fifty Two Week Change Percent | -29.010237 |
| Fifty Two Week High | 7.18 |
| Fifty Two Week High Change | -3.5749998 |
| Fifty Two Week High Change Percent | -0.49791086 |
| Fifty Two Week Low | 2.77 |
| Fifty Two Week Low Change | 0.83500004 |
| Fifty Two Week Low Change Percent | 0.30144405 |
| Fifty Two Week Range | 2.77 - 7.18 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,618,579,800,000 |
| Float Shares | 518,511,012 |
| Forward Eps | -0.90189 |
| Forward P E | -3.9971616 |
| Free Cashflow | -219,493,744 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 600 |
| Fullday Change | -0.5549998 |
| Fullday Change Percent | -13.341343 |
| Fullday Price | 3.605 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Gross Profits | -392,600,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01832 |
| Held Percent Institutions | 0.64435995 |
| Implied Shares Outstanding | 536,271,087 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-04-16 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah. |
| Long Name | Recursion Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 1,933,257,216 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_261401243 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -518,884,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,003,544,156 |
| Number Of Analyst Opinions | 6 |
| Open | 4.11 |
| Operating Cashflow | -350,480,992 |
| Operating Margins | -17.59687 |
| Overall Risk | 10 |
| Phone | 385 269 0203 |
| Previous Close | 4.16 |
| Price Eps Current Year | -3.894855 |
| Price Hint | 4 |
| Price To Book | 2.1081872 |
| Price To Sales Trailing12 Months | 35.2424 |
| Profit Margins | 0.0 |
| Quick Ratio | 4.672 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.42857 |
| Region | US |
| Regular Market Change | -0.5549998 |
| Regular Market Change Percent | -13.341343 |
| Regular Market Day High | 4.185 |
| Regular Market Day Low | 3.605 |
| Regular Market Day Range | 3.605 - 4.185 |
| Regular Market Open | 4.11 |
| Regular Market Previous Close | 4.16 |
| Regular Market Price | 3.605 |
| Regular Market Time | 1,792,168,685 |
| Regular Market Volume | 20,056,927 |
| Return On Assets | -0.27334 |
| Return On Equity | -0.5658 |
| Revenue Growth | -0.601 |
| Revenue Per Share | 0.108 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 10 |
| Shares Outstanding | 535,342,170 |
| Shares Percent Shares Out | 0.2945 |
| Shares Short | 157,938,412 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 179,145,796 |
| Short Name | Recursion Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.3089 |
| Short Ratio | 7.82 |
| Source Interval | 15 |
| State | UT |
| Symbol | RXRX |
| Target High Price | 10.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 7.31667 |
| Target Median Price | 7.0 |
| Total Cash | 545,683,008 |
| Total Cash Per Share | 1.019 |
| Total Debt | 66,638,000 |
| Total Revenue | 54,856,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.09 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.5658 |
| Two Hundred Day Average Change | 0.039200068 |
| Two Hundred Day Average Change Percent | 0.010993345 |
| Type Disp | Equity |
| Volume | 20,056,927 |
| Website | https://www.recursion.com |
| Zip | 84,101 |